We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO IP Counsels Committee ConferenceNovember 14-16, 2018
BIO CEO & Investor ConferenceFebruary 11-12, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
Because of the unique capital needs of groundbreaking research, growing biotech companies often turn to the public market for financing.
New Issue Brief on Co-Pay Accumulator Programs
The history of selecting animals such as cows, chickens, and pigs with improved genetics has provided steady improvement to their sustainability, welfare and disease resistance.
The history of selecting plants with improved genetics has provided steady improvements including increased yields while using fewer resources and greater resistance to disease and pests.
During the 2018 PAHPA reauthorization process, Congress must continue to send a strong signal that it is committed to prioritizing health security by providing the resources needed to allow the nation to fully prepare for and defend against biological threats.
New, innovative treatments – “Transformative Therapies” – provide a significant, durable benefit and value for patient health outcomes, delivery of care, and overall healthcare spending.
Human genome editing is a process by which a DNA sequence is modified to elicit a desired outcome within a living cell.
Strong patents are the lifeblood of the biotechnology industry.
The Medicare prescription drug program - known as Medicare Part B - provides America's seniors and disabled individuals with access to a wide range of affordable medicines.
Learn about the Pharmaceutical Information Exchange Act of 2017 and its role in helping share information between biopharma innovators and population health decision makers.